MedChunk
Medically reviewed

What Is Pegcetacoplan for Geographic Atrophy?

Learn what pegcetacoplan (Syfovre) is, how it slows geographic atrophy, its effectiveness, injection schedule, potential side effects, and important safety considerations.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 17 min read

Pegcetacoplan is a prescription medicine given as an injection into the eye to slow the growth of geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Sold under the brand name Syfovre in the United States, it works by blocking a part of the immune system that contributes to damage in the retina. Although it can slow the progression of geographic atrophy, it does not restore vision that has already been lost.

What Is Geographic Atrophy, and Why Is It Treated?

Geographic atrophy (GA) is an advanced form of dry AMD. It develops when important cells in the retina gradually break down and die. The retina is the light-sensitive layer at the back of the eye, while the macula is the central area responsible for sharp vision. The National Eye Institute explains that damage to the macula can affect central vision, making activities such as reading, recognizing faces, driving, and seeing fine details more difficult. Geographic atrophy causes areas of retinal damage to expand over time. These damaged areas may involve the center of the macula or develop around it before reaching the central region. Some people may notice: - Blurry or missing areas in their central vision. - Difficulty reading small print. - Trouble recognizing familiar faces. - Reduced ability to see details in dim lighting. - Increasing difficulty with everyday activities requiring sharp vision. The speed of progression and its effect on vision vary between individuals. Previously, treatment options for geographic atrophy were limited. Pegcetacoplan introduced a treatment approach that targets part of the immune system involved in the disease process rather than attempting to repair already damaged retinal cells.

How Does Pegcetacoplan Work in the Eye?

Pegcetacoplan works by blocking a protein called complement component 3, commonly known as C3. C3 is part of the complement system, a group of proteins that help the immune system respond to infections and other threats. This system also plays a role in inflammation. In geographic atrophy, abnormal activity in the complement system is thought to contribute to damage in the retina. Excessive activity in this pathway may encourage the loss of retinal cells and the expansion of damaged areas. Pegcetacoplan reduces this activity by attaching to and blocking C3 and its active form, C3b. The treatment works through the following process: 1. **Blocks C3 activity:** Pegcetacoplan binds to C3 and C3b, preventing normal activation of the complement pathway. 2. **Reduces complement activity:** This limits activity in a part of the immune system associated with retinal damage. 3. **Slows the growth of damaged areas:** By targeting this pathway, the medicine can reduce the rate at which geographic atrophy lesions expand. According to the European Medicines Agency (EMA), pegcetacoplan was developed to block C3 activity and slow the growth of geographic atrophy lesions. Importantly, slowing the growth of an existing damaged area is different from restoring the retinal cells that have already been lost. Pegcetacoplan is intended to slow further disease progression, not reverse existing damage.

What Is Syfovre, and Is It the Same as Pegcetacoplan?

Syfovre is the brand name for pegcetacoplan. Pegcetacoplan is the active ingredient responsible for the medicine's effects. The US Food and Drug Administration (FDA) approved Syfovre on February 17, 2023, for treating geographic atrophy secondary to age-related macular degeneration. It was the first FDA-approved medicine specifically indicated for this condition. Syfovre is administered directly into the eye rather than taken as a tablet, capsule, or eye drop. Its approval and availability differ between countries. For example, the European Medicines Agency confirmed its recommendation to refuse marketing authorization for Syfovre following a review of the available evidence. Therefore, US approval should not be taken as confirmation that the medicine is approved or available everywhere. The EMA's assessment of Syfovre provides information about its proposed use, clinical evidence, and European regulatory decision.

Who May Be a Candidate for Pegcetacoplan?

Pegcetacoplan is intended for adults with geographic atrophy caused by age-related macular degeneration. However, having geographic atrophy does not automatically mean that someone should receive this treatment. An ophthalmologist, particularly a retina specialist, evaluates the potential benefits and risks before recommending repeated injections. Factors that may be considered include: - **Location of retinal damage:** The specialist examines whether the damaged areas affect the central macula or are located elsewhere. - **Extent of geographic atrophy:** The size and distribution of damaged areas help assess the condition. - **Changes over time:** Previous retinal scans and examinations can help show how quickly the affected areas are growing. - **Existing visual function:** The amount of useful vision remaining and its effect on daily activities are important considerations. - **Other eye conditions:** A history of eye inflammation, infections, wet AMD, or other retinal problems may influence treatment decisions. - **Treatment commitment:** The person needs to consider the repeated injections and follow-up appointments involved. Pegcetacoplan may be considered when the ophthalmologist believes that slowing further retinal damage offers a meaningful potential benefit. It is not appropriate for every person with geographic atrophy, and the decision should account for both the expected benefit and the possibility of complications.

How Is Pegcetacoplan Administered?

Pegcetacoplan is given through an intravitreal injection. This means that the medicine is injected into the vitreous, the gel-like substance inside the eye. The injection is performed by a qualified eye specialist using sterile techniques. The usual treatment process involves: 1. **Preparing the eye:** The eye and surrounding area are cleaned to reduce the risk of infection. 2. **Numbing the eye:** Anesthetic eye drops or another appropriate method are used to reduce discomfort. 3. **Giving the injection:** The specialist places the medicine into the vitreous cavity using a fine needle. 4. **Checking the eye:** The eye is assessed after the procedure to monitor pressure and identify any immediate complications. The procedure usually takes only a short time, although the complete clinic visit may take longer because of preparation and monitoring. A person may experience temporary pressure, irritation, mild discomfort, or redness after the injection.

How Often Are Pegcetacoplan Injections Given?

According to the US prescribing information published on DailyMed, the recommended dose of Syfovre is: - 15 mg of pegcetacoplan in 0.1 mL of solution. - Administered into each affected eye. - Given once every 25 to 60 days. In practice, this generally corresponds to monthly or every-other-month treatment. The ophthalmologist determines the appropriate schedule based on the treatment plan and the individual's circumstances. Because geographic atrophy is a progressive condition, treatment generally involves repeated injections rather than a single dose. Regular follow-up is important to assess disease progression, treatment response, and possible adverse effects. The official Syfovre prescribing information on DailyMed provides the recommended dose, administration instructions, contraindications, and safety warnings.

How Effective Is Pegcetacoplan for Geographic Atrophy?

Clinical trials have shown that pegcetacoplan can slow the enlargement of geographic atrophy lesions. Two major clinical trials, called OAKS and DERBY, evaluated the medicine in adults with geographic atrophy secondary to AMD. Together, these studies included 1,258 participants. Researchers compared monthly pegcetacoplan injections and injections given every other month with sham injections, which involved a simulated procedure without the active medicine. The main goal was to measure changes in the size of geographic atrophy lesions.

What Did the OAKS and DERBY Trials Find?

After 24 months, the researchers reported the following reductions in geographic atrophy lesion growth compared with the control groups:
Clinical trial Monthly treatment Every-other-month treatment
OAKS 22% reduction 18% reduction
DERBY 19% reduction 16% reduction
These results indicate that the medicine reduced the rate at which damaged retinal areas expanded. However, an important distinction emerged from the findings. At 24 months, the studies did not demonstrate significant differences in their key secondary measures of visual function, including important assessments of visual acuity and reading-related function. In other words, the medicine slowed the physical growth of retinal damage, but this did not translate into a demonstrated improvement in eyesight during the main trial period. The findings were published in *The Lancet* in 2023. The OAKS and DERBY clinical trial publication on PubMed provides the full study results.

Does Pegcetacoplan Restore Lost Vision?

No. Pegcetacoplan has not been shown to restore vision that has already been lost because of geographic atrophy. The medicine targets the biological process involved in the expansion of retinal damage. It does not replace dead retinal cells or repair areas that have already become atrophic. Its potential benefit is in slowing further enlargement of damaged areas, which may help preserve retinal tissue for longer. The distinction is important when considering treatment expectations. Someone considering pegcetacoplan should understand that: - Existing retinal damage generally remains. - Previously lost central vision is not expected to return because of this medicine. - Disease progression may continue even during treatment. - The extent of benefit differs between individuals. - Repeated injections and monitoring are generally necessary. Treatment decisions should therefore focus on whether slowing further damage is worth the injection schedule and potential risks in a particular case.

What Are the Side Effects of Pegcetacoplan?

Pegcetacoplan can cause side effects ranging from temporary injection-related symptoms to serious complications affecting vision. Some reactions are relatively common, while others are less common but require immediate medical attention.

Common Side Effects

The most frequently reported adverse reactions in the clinical trials included: - **Eye discomfort:** Temporary irritation, soreness, or an uncomfortable feeling in the treated eye. - **Vitreous floaters:** Small spots or shapes that appear to move through the field of vision. - **Conjunctival hemorrhage:** Bleeding beneath the clear membrane covering the white part of the eye, often appearing as a red patch. - **Neovascular AMD:** Development of abnormal blood vessels associated with the wet form of age-related macular degeneration. Some people may also experience temporary blurred vision or irritation following an injection. Not every person receiving pegcetacoplan experiences these effects.

Increased Risk of Wet Age-Related Macular Degeneration

One important concern is the development of neovascular, or wet, AMD. This condition involves abnormal blood vessels growing beneath or within the retina. These vessels may leak fluid or blood and cause further damage to central vision. In the OAKS and DERBY clinical trials, the rates of new-onset neovascular AMD or choroidal neovascularization by month 24 were: - 12% among participants receiving monthly pegcetacoplan. - 7% among participants receiving pegcetacoplan every other month. - 3% among participants in the control group. These findings indicate that pegcetacoplan treatment was associated with an increased risk of developing wet AMD during the study period. Patients receiving treatment may need regular retinal examinations to identify this complication. When wet AMD develops, a separate treatment, such as an anti-VEGF injection, may be required.

Retinal Vasculitis and Retinal Blood Vessel Blockage

One of the most important safety concerns associated with pegcetacoplan is retinal vasculitis. Retinal vasculitis is inflammation affecting the blood vessels in the retina. In some cases, inflammation can be accompanied by retinal vascular occlusion, meaning that blood flow through a retinal blood vessel becomes blocked. These complications can cause severe vision loss. According to the current US prescribing information, retinal vasculitis and retinal vascular occlusion have been reported after Syfovre treatment. These events may occur after the first injection and can lead to serious visual complications. The American Society of Retina Specialists (ASRS) reported a review of confirmed post-injection retinal vasculitis cases through January 16, 2024. The review identified 14 affected eyes in 13 patients. Some cases involved significant and lasting vision loss. This was a review of reported cases, not a study that could establish the overall frequency of the complication. Nevertheless, it highlights the importance of understanding this serious potential risk. The ASRS Research and Safety in Therapeutics Committee report provides further information about these cases.

Other Serious Complications

Additional complications associated with intravitreal pegcetacoplan treatment include: - **Endophthalmitis:** A serious infection inside the eye that can threaten vision. - **Retinal detachment:** Separation of the retina from the supporting tissue beneath it. - **Intraocular inflammation:** Inflammation inside the eye, which may affect different structures. - **Increased eye pressure:** A temporary rise in pressure inside the eye may occur shortly after the injection. - **Severe allergic reactions:** Postmarketing reports have included anaphylaxis, rash, and urticaria. These complications are not expected in everyone, but they are important to recognize before starting treatment.

When Should Someone Seek Medical Attention After an Injection?

Certain symptoms following pegcetacoplan treatment require prompt assessment by an ophthalmologist. Contact the treating eye specialist immediately if any of the following occur: - New or worsening eye pain. - Increasing redness of the eye. - Sensitivity to light. - Sudden or worsening blurred vision. - New flashes of light. - A sudden increase in floaters. - New distortion or changes in vision. These symptoms may be associated with inflammation, infection, retinal detachment, or retinal blood vessel complications. A person should not wait for a scheduled follow-up appointment if a new or concerning change in vision occurs after treatment.

Who Should Not Receive Pegcetacoplan?

According to the US prescribing information, Syfovre is contraindicated in certain circumstances. It should not be administered to people with: - An active infection in the eye or surrounding area. - Active inflammation inside the eye. - A known hypersensitivity to pegcetacoplan or an ingredient in the medicine. These restrictions help reduce the risk of complications. A person's eye history, current examination findings, and other relevant medical information should be reviewed before treatment begins. The ophthalmologist may also need to reconsider treatment if inflammation, infection, or another significant eye complication develops during therapy.

How Is Treatment Monitored Over Time?

Monitoring is an important part of pegcetacoplan treatment because slowing geographic atrophy does not mean that the condition has stopped progressing. An ophthalmologist may use several methods to evaluate the eye. **Dilated retinal examination:** The specialist examines the retina and macula to assess the extent of retinal damage and look for other abnormalities. **Optical coherence tomography (OCT):** This imaging test produces detailed cross-sectional pictures of the retina. It helps clinicians evaluate retinal structures and monitor changes over time. **Fundus autofluorescence imaging:** This imaging technique helps identify and measure areas of geographic atrophy. **Visual function assessment:** Eye examinations may include tests of visual acuity and other aspects of vision to understand how retinal changes are affecting daily activities. Monitoring also helps identify possible complications, particularly the development of wet AMD or inflammation inside the eye. The treating specialist uses these findings to assess whether continued injections remain appropriate.

What Should Patients Consider Before Starting Pegcetacoplan?

Pegcetacoplan offers an additional treatment option for a condition that previously had limited ways to slow its progression. However, the decision to receive repeated eye injections involves more than considering the percentage reduction in lesion growth. It is useful to discuss the following points with a retina specialist: **Expected benefit:** Ask how much slowing of geographic atrophy progression might reasonably be expected and whether the location of the existing damage affects the potential benefit. **Treatment schedule:** Clarify how frequently injections may be needed and how often follow-up examinations will take place. **Possible complications:** Discuss retinal vasculitis, vascular occlusion, wet AMD, infection, and other injection-related risks. **Existing vision:** Understand that treatment is intended to slow further retinal damage rather than restore vision already lost. **Long-term commitment:** Consider the repeated appointments, travel, financial costs, and ongoing monitoring involved. **Other treatment options:** Discuss whether observation, low-vision support, or another locally approved treatment may be more suitable. The most appropriate approach depends on the expected benefits, potential complications, and the individual's priorities.

Frequently Asked Questions About Pegcetacoplan

These answers address common questions about the use of pegcetacoplan for geographic atrophy and what patients can expect from treatment.

Is pegcetacoplan a cure for geographic atrophy?

No. Pegcetacoplan is not a cure for geographic atrophy. It can slow the enlargement of damaged areas in the retina, but it does not repair existing retinal damage or restore lost vision.

How long does pegcetacoplan treatment take to work?

Pegcetacoplan is intended to slow the progression of geographic atrophy over time. Its effect is assessed by comparing retinal imaging and examination findings over repeated visits. It is not designed to produce an immediate improvement in eyesight.

Can pegcetacoplan cause blindness?

Serious complications, including retinal vasculitis and retinal vascular occlusion, have been reported and may cause severe vision loss. These complications are not expected in everyone, but any new vision change, eye pain, redness, or light sensitivity after an injection requires immediate assessment.

How often does someone need Syfovre injections?

The US prescribing information recommends 15 mg administered into each affected eye once every 25 to 60 days. This generally means monthly or every-other-month injections, depending on the treatment schedule selected by the ophthalmologist.

Is pegcetacoplan approved in every country?

No. Regulatory approval differs between countries. The medicine is FDA-approved in the United States for geographic atrophy secondary to AMD, while the European Medicines Agency confirmed a recommendation to refuse marketing authorization for Syfovre in 2024. Patients should check local approval and availability with an ophthalmologist.

Frequently Asked Questions

Additional points about understanding pegcetacoplan treatment for geographic atrophy.

Does pegcetacoplan stop geographic atrophy completely?

No. Pegcetacoplan slows the growth of geographic atrophy lesions but does not completely stop the disease. Progression may continue during treatment.

Can both eyes receive pegcetacoplan?

Yes. The medicine may be administered to each affected eye when clinically appropriate. The ophthalmologist determines which eyes require treatment and plans the injection schedule.

Does pegcetacoplan treat wet AMD?

No. Pegcetacoplan is indicated for geographic atrophy secondary to AMD, not as a treatment for wet AMD. If wet AMD develops, a separate treatment such as an anti-VEGF injection may be needed.

Can someone stop pegcetacoplan injections once their vision stabilizes?

There is no universal stopping schedule. The ophthalmologist evaluates retinal changes, visual function, treatment benefits, and safety concerns before deciding whether to continue, change, or discontinue injections.

Is pegcetacoplan suitable for someone with an eye infection?

No. An active eye or surrounding-eye infection is a contraindication to Syfovre treatment. Treatment should not proceed until the infection has been appropriately evaluated and managed.

Citations

  1. National Eye Institute (NEI) – Age-Related Macular Degeneration
  2. DailyMed – Syfovre (Pegcetacoplan) Official Prescribing Information
  3. The Lancet / PubMed – Pegcetacoplan for the Treatment of Geographic Atrophy: OAKS and DERBY Phase 3 Trials
  4. European Medicines Agency – Syfovre Assessment and Marketing Authorization Decision
  5. American Society of Retina Specialists – ReST Committee Report on Retinal Vasculitis Following Syfovre Injection
Share this article